{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:55:45Z","timestamp":1793436945135,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["RP-PG-051420018"],"award-info":[{"award-number":["RP-PG-051420018"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rapid molecular diagnostics such as the BioFire FilmArray Pneumonia Panel (the Pneumonia Panel) can improve antibiotic stewardship by supporting doctors to make more targeted antibiotic prescribing decisions faster compared to routine microbiology. However, factors influencing how these test results translate to individual prescribing decisions are poorly understood. The INHALE randomised controlled trial (RCT) evaluated the application of the Pneumonia Panel to manage suspected hospital-acquired and ventilator-associated pneumonias (HAP\/VAP) in English intensive care unit (ICU) patients. This behavioural study examines clinicians perceived and actual antibiotic prescribing behaviour, within the INHALE RCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinicians treating ICU patients completed brief questionnaires within 24\u00a0h of their prescribing decision for intervention-arm cases (N\u2009=\u2009159), exploring factors influencing their decision and perceptions about the test results. Actual prescribing behaviour was extracted from the trial database. A 4-block hierarchical logistic regression identified predictors of prescriptions being consistent with Pneumonia Panel results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      65% (N\u2009=\u2009104) of prescribing decisions were consistent with Pneumonia Panel results. The test result itself was a dominant factor: 88% (N\u2009=\u200998) of decisions were consistent when results were positive (pathogens found). However, only 13% (N\u2009=\u20096) of decisions were consistent when no pathogens were detected. Consequently, clinicians were often reluctant to eschew initial antibiotics or de-escalate early where appropriate, \u2018\n                      <jats:italic>erring on the side of caution<\/jats:italic>\n                      \u2019. Clinicians perceptions, specifically the speed of results, concurrent antibiotic treatment, the patient having additional confirmed evidence of infection, and believing the patient is unlikely to have a non-respiratory infection predicted prescribing decisions being aligned with test results (all p\u2009&lt;\u2009.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Findings have implications for the roll-out of rapid diagnostics in practice, particularly regarding the management of negative results. Implementation strategies need to be behaviourally intelligent, connecting with how clinicians think and behave.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13756-025-01690-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:05:24Z","timestamp":1774371924000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians\u2019 perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2396-9028","authenticated-orcid":false,"given":"Sarah-Jane F.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virve I.","family":"Enne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M.","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogini H.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brealey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Brett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Livermore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanya","family":"Gant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the INHALE WP Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Barber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaneeta","family":"Dhesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Colles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Dresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Marie","family":"Swart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Welters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"de Neef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suveer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeela","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"12","key":"1690_CR1","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00134-019-05797-6","volume":"45","author":"I Martin-Loeches","year":"2019","unstructured":"Martin-Loeches I, Torres A, Povoa P, Zampieri FG, Salluh J, Nseir S, et al. The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. Intensive Care Med. 2019;45(12):1753\u201362.","journal-title":"Intensive Care Med"},{"key":"1690_CR2","unstructured":"BioFire Diagnostics [Internet]. [cited 2022 Feb 11]. The BioFire\u00ae FilmArray\u00ae Pneumonia Panel. Available from: https:\/\/www.biofiredx.com\/products\/the-filmarray-panels\/filmarray-pneumonia\/"},{"key":"1690_CR3","unstructured":"Unyvero A50 Molecular Diagnostic Platform Curetis [Internet]. Curetis. [cited 2022 July 28]. Available from: https:\/\/curetis.com\/products\/unyvero-a50-system\/"},{"issue":"1","key":"1690_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2019.11.021","volume":"80","author":"S Poole","year":"2020","unstructured":"Poole S, Clark TW. Rapid syndromic molecular testing in pneumonia: The current landscape and future potential. J Infect. 2020;80(1):1\u20137.","journal-title":"J Infect"},{"issue":"6","key":"1690_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jinf.2022.09.003","volume":"85","author":"S Poole","year":"2022","unstructured":"Poole S, Tanner AR, Naidu VV, Borca F, Phan H, Saeed K, et al. Molecular point-of-care testing for lower respiratory tract pathogens improves safe antibiotic de-escalation in patients with pneumonia in the ICU: Results of a randomised controlled trial. J Infect. 2022;85(6):625\u201333.","journal-title":"J Infect"},{"issue":"9","key":"1690_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-2600(22)00086-8","volume":"10","author":"AM Darie","year":"2022","unstructured":"Darie AM, Khanna N, Jahn K, Osthoff M, Bassetti S, Osthoff M, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med. 2022;10(9):877\u201387.","journal-title":"Lancet Respir Med"},{"key":"1690_CR7","unstructured":"Pandolfo AM, Horne R, Jani Y, Reader TW, Bidad N, Brealey D, et al. Understanding decisions about antibiotic prescribing in ICU: an application of the Necessity Concerns Framework. BMJ Qual Saf [Internet]. 2021 June 7 [cited 2022 Feb 11]; Available from: https:\/\/qualitysafety.bmj.com\/content\/early\/2021\/06\/07\/bmjqs-2020-012479"},{"issue":"1","key":"1690_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13756-021-00961-4","volume":"10","author":"AM Pandolfo","year":"2021","unstructured":"Pandolfo AM, Horne R, Jani Y, Reader TW, Bidad N, Brealey D, et al. Intensivists\u2019 beliefs about rapid multiplex molecular diagnostic testing and its potential role in improving prescribing decisions and antimicrobial stewardship: a qualitative study. Antimicrob Resist Infect Control. 2021;10(1):95.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"1690_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/dkad355","volume":"79","author":"SJF Stewart","year":"2024","unstructured":"Stewart SJF, Pandolfo AM, Moon Z, Jani Y, Brett SJ, Brealey D, et al. UK clinicians\u2019 attitudes towards the application of molecular diagnostics to guide antibiotic use in ICU patients with pneumonias: a quantitative study. J Antimicrob Chemother. 2024;79(1):123\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"1690_CR10","doi-asserted-by":"publisher","unstructured":"Stewart SJF, Pandolfo AM, Jani Y, Moon Z, Brealey D, Enne VI, et al. Guidelines vs mindlines: a qualitative investigation of how clinicians\u2019 beliefs influence the application of rapid molecular diagnostics in intensive care. Antimicrobial Agents and Chemotherapy [Internet]. 2025 Mar 5 [cited 2025 Mar 21]; Available from: https:\/\/journals.asm.org\/doi\/https:\/\/doi.org\/10.1128\/aac.01156-24","DOI":"10.1128\/aac.01156-24"},{"issue":"1","key":"1690_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1186\/s13063-021-05618-6","volume":"22","author":"J High","year":"2021","unstructured":"High J, Enne VI, Barber JA, Brealey D, Turner DA, Horne R, et al. INHALE: the impact of using FilmArray Pneumonia Panel molecular diagnostics for hospital-acquired and ventilator-associated pneumonia on antimicrobial stewardship and patient outcomes in UK Critical Care\u2014study protocol for a multicentre randomised controlled trial. Trials. 2021;22(1):680.","journal-title":"Trials"},{"key":"1690_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-024-07772-2","author":"VI Enne","year":"2025","unstructured":"Enne VI, Stirling S, Barber JA, High J, Russell C, Brealey D, et al. INHALE WP3, a multicentre, open-label, pragmatic randomised controlled trial assessing the impact of rapid, ICU-based, syndromic PCR, versus standard-of-care on antibiotic stewardship and clinical outcomes in hospital-acquired and ventilator-associated pneumonia. Intensive Care Med. 2025. https:\/\/doi.org\/10.1007\/s00134-024-07772-2.","journal-title":"Intensive Care Med"},{"issue":"6","key":"1690_CR13","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/aje\/kwk052","volume":"165","author":"E Vittinghoff","year":"2007","unstructured":"Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol. 2007;165(6):710\u20138.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"1690_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jclinepi.2004.06.017","volume":"58","author":"Y Vergouwe","year":"2005","unstructured":"Vergouwe Y, Steyerberg EW, Eijkemans MJC, Habbema JDF. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 2005;58(5):475\u201383.","journal-title":"J Clin Epidemiol"},{"key":"1690_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.clinpsy.3.022806.091415","volume":"4","author":"S Shiffman","year":"2008","unstructured":"Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol. 2008;4:1\u201332.","journal-title":"Annu Rev Clin Psychol"},{"issue":"6","key":"1690_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/imj.12373","volume":"44","author":"NJ Chaves","year":"2014","unstructured":"Chaves NJ, Cheng AC, Runnegar N, Kirschner J, Lee T, Buising K. Analysis of knowledge and attitude surveys to identify barriers and enablers of appropriate antimicrobial prescribing in three Australian tertiary hospitals. Intern Med J. 2014;44(6):568\u201374.","journal-title":"Intern Med J"},{"issue":"4","key":"1690_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/0897190018821265","volume":"32","author":"SM Smoke","year":"2019","unstructured":"Smoke SM, Centrella M, Grigoriu A, Brust-Sisti L. Antibiotic decision-making among medical residents, medical students, and nurse practitioners: a single-center survey. J Pharm Pract. 2019;32(4):372\u20134.","journal-title":"J Pharm Pract"},{"issue":"16","key":"1690_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12879-016-1665-1","volume":"22","author":"N Safdar","year":"2016","unstructured":"Safdar N, Musuuza JS, Xie A, Hundt AS, Hall M, Wood K, et al. Management of ventilator-associated pneumonia in intensive care units: a mixed methods study assessing barriers and facilitators to guideline adherence. BMC Infect Dis. 2016;22(16):349.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"1690_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.12953","volume":"82","author":"HM Parker","year":"2016","unstructured":"Parker HM, Mattick K. The determinants of antimicrobial prescribing among hospital doctors in England: a framework to inform tailored stewardship interventions. Br J Clin Pharmacol. 2016;82(2):431\u201340.","journal-title":"Br J Clin Pharmacol"},{"key":"1690_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13756-015-0065-4","volume":"4","author":"B Skodvin","year":"2015","unstructured":"Skodvin B, Aase K, Charani E, Holmes A, Smith I. An antimicrobial stewardship program initiative: a qualitative study on prescribing practices among hospital doctors. Antimicrob Resist Infect Control. 2015;4:24.","journal-title":"Antimicrob Resist Infect Control"},{"key":"1690_CR21","unstructured":"Jamovi [Internet]. Sydney, Australia; Available from: https:\/\/www.jamovi.org"},{"issue":"8","key":"1690_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2024.26458","volume":"333","author":"P Dark","year":"2025","unstructured":"Dark P, Hossain A, McAuley DF, Brealey D, Carlson G, Clayton JC, et al. Biomarker-guided antibiotic duration for hospitalized patients with suspected sepsis: The ADAPT-Sepsis Randomized Clinical Trial. JAMA. 2025;333(8):682\u201393.","journal-title":"JAMA"},{"issue":"2","key":"1690_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S2213-2600(19)30367-4","volume":"8","author":"TP Hellyer","year":"2020","unstructured":"Hellyer TP, McAuley DF, Walsh TS, Anderson N, Morris AC, Singh S, et al. Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation. Lancet Respir Med. 2020;8(2):182\u201391.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1690_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-084872","volume":"14","author":"T Lau","year":"2024","unstructured":"Lau T, Nurek M, Singhal A, Moore L, Mughal N, Singh S. Point-of-care tests, diagnostic uncertainty and antimicrobial stewardship in the ICU: procalcitonin or PCR to aid antibiotic-stop decisions \u2013 an observational cohort study. BMJ Open. 2024;14(12):e084872.","journal-title":"BMJ Open"},{"issue":"11","key":"1690_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-073577","volume":"13","author":"S Singh","year":"2023","unstructured":"Singh S, Nurek M, Mason S, Moore LS, Mughal N, Vizcaychipi MP. WHY STOP? A prospective observational vignette-based study to determine the cognitive-behavioural effects of rapid diagnostic PCR-based point-of-care test results on antibiotic cessation in ICU infections. BMJ Open. 2023;13(11):e073577.","journal-title":"BMJ Open"},{"issue":"7473","key":"1690_CR26","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1136\/bmj.329.7473.1013","volume":"329","author":"J Gabbay","year":"2004","unstructured":"Gabbay J, le May A. Evidence based guidelines or collectively constructed \u201cmindlines?\u201d Ethnographic study of knowledge management in primary care. BMJ. 2004;329(7473):1013.","journal-title":"BMJ"},{"issue":"649","key":"1690_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3399\/bjgp16X686221","volume":"66","author":"J Gabbay","year":"2016","unstructured":"Gabbay J, le May A. Mindlines: making sense of evidence in practice. Br J Gen Pract. 2016;66(649):402\u20133.","journal-title":"Br J Gen Pract"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-025-01690-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01690-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:01:44Z","timestamp":1774537304000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13756-025-01690-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1186\/s13756-025-01690-8","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The INHALE research programme received ethical approval from the London\u2014Brighton & Sussex Research Ethics Committee (19\/LO\/0400).We received Health Research Authority approval to use informed implied consent (where completion of the questionnaire denoted consent) for this study, and it was exempt from research ethics review under prevailing UK regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DB reports personal fees (lecture fees) from bioM\u00e9rieux, outside the submitted work. VIE reports consultancy fees and non-financial support from bioM\u00e9rieux, personal fees from Curetis GmbH, and non-financial support from Oxford Nanopore Technologies and Inflammatix Inc, outside the submitted work. RH is supported by the National Institute for Health Research (NIHR, Collaboration for Leadership in Applied Health Research and Care (CLAHRC), North Thames at Bart's Health NHS Trust and Asthma UK (AUKCAR). He reports speaker engagements with honoraria from AbbVie, Abbott, Amgen, Astellas, AstraZeneca, bioM\u00e9rieux, Boehringer Ingelheim, Biogen, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Shire Pharmaceuticals, TEVA, UCB and personal consultancy with Amgen, Abbott, AstraZeneca and Novartis. He is Founding Director of a UCL-Business company (Spoonful of Sugar Ltd) providing consultancy on treatment engagement and patient support programmes to healthcare policy makers, providers and pharmaceutical industry. SJB reports a consultancy payment to his university account from GSK for work outside this area. DML reports Adjutec, AstraZeneca, bioM\u00e9rieux, Centauri, GenPax, GSK, Hikma, Merck\/MSD, Nordic, Paion, Pfizer, Shionogi, Sumitovant, Summit, Thermofisher, Wockhardt and Zambon, He also reports shareholdings from GenPax, GSK, Merck, Oxford Nanopore and PerkinElmer\/Revvity, comprising less than 10% of portfolio value. He also has nominated holdings in Arecor, Celadon Pharmaceuticals, Destiny Pharma, Eluceda Ltd., Genedrive, Poolbeg, Optibiotix, Probiotix Health, SkinBiotherapeutics, Trellus and Verici Dx (all of which have research\/products pertinent to medical and diagnostic innovation) through Enterprise Investment Schemes but has no authority to trade these shares directly. All are outside the submitted work. VG reports receiving speaking honoraria from bioM\u00e9rieux and support for conference attendances from Merck\/MSD and Gilead, outside the submitted work. Other authors have no potential conflicts of interest.VIE reports consultancy fees and non-financial support from bioM\u00e9rieux, personal fees from Curetis GmbH, and non-financial support from Oxford Nanopore Technologies and Inflammatix Inc, outside the submitted work.RH is supported by the National Institute for Health Research (NIHR, Collaboration for Leadership in Applied Health Research and Care (CLAHRC), North Thames at Bart's Health NHS Trust and Asthma UK (AUKCAR). He reports speaker engagements with honoraria from AbbVie, Abbott, Amgen, Astellas, AstraZeneca, bioM\u00e9rieux, Boehringer Ingelheim, Biogen, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp Dohme, Merck, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, Shire Pharmaceuticals, TEVA, UCB and personal consultancy with Amgen, Abbott, AstraZeneca and Novartis. He is Founding Director of a UCL-Business company (Spoonful of Sugar Ltd) providing consultancy on treatment engagement and patient support programmes to healthcare policy makers, providers and pharmaceutical industry.SJB reports a consultancy payment to his university account from GSK for work outside this area.DML reports Adjutec, AstraZeneca, bioM\u00e9rieux, Centauri, GenPax, GSK, Hikma, Merck\/MSD, Nordic, Paion, Pfizer, Shionogi, Sumitovant, Summit, Thermofisher, Wockhardt and Zambon, He also reports shareholdings from GenPax, GSK, Merck, Oxford Nanopore and PerkinElmer\/Revvity, comprising less than 10% of portfolio value. He also has nominated holdings in Arecor, Celadon Pharmaceuticals, Destiny Pharma, Eluceda Ltd., Genedrive, Poolbeg, Optibiotix, Probiotix Health, SkinBiotherapeutics, Trellus and Verici Dx (all of which have research\/products pertinent to medical and diagnostic innovation) through Enterprise Investment Schemes but has no authority to trade these shares directly. All are outside the submitted work.VG reports receiving speaking honoraria from bioM\u00e9rieux and support for conference attendances from Merck\/MSD and Gilead, outside the submitted work.Other authors have no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}